Biochemical Mechanisms beyond Glycosphingolipid Accumulation in Fabry Disease: Might They Provide Additional Therapeutic Treatments?

• Published in: Journal of clinical medicine 2023-03, Vol.12 (5), p.2063
• Main Authors: Bertoldi, Giovanni, Caputo, Ilaria, Driussi, Giulia, Stefanelli, Lucia Federica, Di Vico, Valentina, Carraro, Gianni, Nalesso, Federico, Calò, Lorenzo A
• Format: Article
• Language: English
• Subjects: Biomarkers; Cardiomyopathy; Care and treatment; Cellular signal transduction; Clinical medicine; Complications and side effects; Development and progression; Enzymes; Fabry's disease; Gene therapy; Genotype & phenotype; Health aspects; Kidney diseases; Males; Mutation; Oxidative stress; Plasma; Review; Sphingolipids
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm12052063

Fabry disease is a rare X-linked disease characterized by deficient expression and activity of alpha-galactosidase A (α-GalA) with consequent lysosomal accumulation of glycosphingolipid in various organs. Currently, enzyme replacement therapy is the cornerstone of the treatment of all Fabry patients, although in the long-term it fails to completely halt the disease's progression. This suggests on one hand that the adverse outcomes cannot be justified only by the lysosomal accumulation of glycosphingolipids and on the other that additional therapies targeted at specific secondary mechanisms might contribute to halt the progression of cardiac, cerebrovascular, and renal disease that occur in Fabry patients. Several studies reported how secondary biochemical processes beyond Gb3 and lyso-Gb3 accumulation-such as oxidative stress, compromised energy metabolism, altered membrane lipid, disturbed cellular trafficking, and impaired autophagy-might exacerbate Fabry disease adverse outcomes. This review aims to summarize the current knowledge of these pathogenetic intracellular mechanisms in Fabry disease, which might suggest novel additional strategies for its treatment.